200 related articles for article (PubMed ID: 12553557)
21. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.
Colao A; Marzullo P; Cuocolo A; Spinelli L; Pivonello R; Bonaduce D; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2003 Feb; 58(2):169-76. PubMed ID: 12580932
[TBL] [Abstract][Full Text] [Related]
22. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.
Bogazzi F; Lombardi M; Strata E; Aquaro G; Lombardi M; Urbani C; Di Bello V; Cosci C; Sardella C; Talini E; Martino E
J Endocrinol Invest; 2010 Feb; 33(2):103-8. PubMed ID: 20348836
[TBL] [Abstract][Full Text] [Related]
23. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
Lim MJ; Barkan AL; Buda AJ
Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
[TBL] [Abstract][Full Text] [Related]
24. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
25. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
Díez JJ; Iglesias P; Gómez-Pan A
J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
[TBL] [Abstract][Full Text] [Related]
27. Clinical results of long-term slow-release lanreotide treatment of acromegaly.
Giusti M; Ciccarelli E; Dallabonzana D; Delitala G; Faglia G; Liuzzi A; Gussoni G; Giordano Disem G
Eur J Clin Invest; 1997 Apr; 27(4):277-84. PubMed ID: 9134375
[TBL] [Abstract][Full Text] [Related]
28. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog.
Manelli F; Bossoni S; Burattin A; Doga M; Solerte SB; Romanelli G; Giustina A
Metabolism; 2000 May; 49(5):634-9. PubMed ID: 10831175
[TBL] [Abstract][Full Text] [Related]
29. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.
Colao A; Marzullo P; Vallone G; Giaccio A; Ferone D; Rossi E; Scarpa R; Smaltino F; Lombardi G
Clin Endocrinol (Oxf); 1999 Nov; 51(5):611-8. PubMed ID: 10594522
[TBL] [Abstract][Full Text] [Related]
30. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
31. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.
Lin JD; Lee ST; Weng HF
Endocr J; 1999 Feb; 46(1):193-8. PubMed ID: 10426587
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
33. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
34. Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly.
Colao A; De Rosa M; Pivonello R; Balestrieri A; Cappabianca P; Di Sarno A; Rochira V; Carani C; Lombardi G
J Clin Endocrinol Metab; 2002 Sep; 87(9):4193-7. PubMed ID: 12213870
[TBL] [Abstract][Full Text] [Related]
35. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment.
Warszawski L; Kasuki L; Sá R; Dos Santos Silva CM; Volschan I; Gottlieb I; Pedrosa RC; Gadelha MR
Pituitary; 2016 Dec; 19(6):582-589. PubMed ID: 27591859
[TBL] [Abstract][Full Text] [Related]
36. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
[TBL] [Abstract][Full Text] [Related]
37. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
38. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.
Couture E; Bongard V; Maiza JC; Bennet A; Caron P
Pituitary; 2012 Dec; 15(4):518-25. PubMed ID: 22058008
[TBL] [Abstract][Full Text] [Related]
39. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
40. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
